Skip to main content

factor IX

Generic: factor IX·Brand: Alphanine SD, Kcentra, Rebinyn

factor IX: 6 clinical trials tracked.

factor IX evidence translation

What we can confirm

6 tracked trials

No verified listed company relationship

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about factor IX, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence1 indications · 1 study sponsors

Related indications

Hemophilia B
Clinical Trial Registry Records (6)

An Observational Post-authorization Long-term Follow-up Study to Characterize the Effectiveness and Safety of HEMGENIX® (Etranacogene Dezaparvovec) in Patients With Hemophilia B

NCT06008938Registry updated 2026-02-19·N/A
Recruiting

Primary endpoint: Bleeding Rate (all bleeds) - HEMGENIX Cohort

Observational500 targetStarted 2023-06Completion 2043-0812 sites · Austria, Denmark, France, Germany…CSL Behring

A Multi-centre, Open-label Trial Evaluating Efficacy, Safety and Pharmacokinetics of Nonacog Beta Pegol When Used for Treatment and Prophylaxis of Bleeding Episodes in Chinese Patients With Haemophilia B

NCT05365217Registry updated 2026-01-12·Phase 3·NVO
Completed

Primary endpoint: Haemostatic Effect of Nonacog Beta Pegol When Used for Treatment of Bleeding Episodes During on Demand and Prophylaxis (PPX)

Interventionalopen30 enrolledStarted 2022-05Completion 2024-0515 sites · ChinaNovo Nordisk A/S

A Non-Interventional Post-Authorisation Safety Study (PASS) in Male Haemophilia B Patients Receiving Nonacog Beta Pegol (N9-GP) Prophylaxis Treatment

NCT03745924Registry updated 2026-06-12·NVO
Enrolling by invitation

Primary endpoint: Number of Adverse Drug Reactions (ADRs) (FIX inhibitors, allergic reactions, and thromboembolic events)

Observational60 targetStarted 2019-04Completion 2027-1230 sites · Austria, Belgium, Canada, Croatia…Novo Nordisk A/S

Adverse Event Data Collection From External Registries on Nonacog Beta Pegol

NCT03690336Registry updated 2026-10-08·NVO
Enrolling by invitation

Primary endpoint: Adverse Drug Reactions (ADRs) reported to the registries with suspected relation to nonacog beta pegol in patients with haemophilia B

Observational10 targetStarted 2018-10Completion 2027-102 sites · Netherlands, United KingdomNovo Nordisk A/S

An Open-label Single-arm Multicentre Non-controlled Phase 3 a Trial Investigating Safety and Efficacy of Nonacog Beta Pegol (N9-GP) in Prophylaxis and Treatment of Bleeding Episodes in Previously Untreated Patients With Haemophilia B (FIX Activity Below or Equal to 2 Percent)

NCT02141074Registry updated 2025-12-23·Phase 3·NVO
Completed

Primary endpoint: Number of Participants With Incidence of Inhibitory Antibodies Against Coagulation Factor IX (FIX) (50 Exposure Days)

Interventionalopen54 enrolledStarted 2014-07Completion 2022-1050 sites · Algeria, Argentina, Australia, Austria…Novo Nordisk A/S

Safety, Efficacy and Pharmacokinetics of NNC-0156-0000-0009 in Previously Treated Children With Haemophilia B

NCT01467427Registry updated 2025-12-23·Phase 3·NVO
Completed

Primary endpoint: Incidence of Inhibitory Antibodies Against Coagulation Factor IX (FIX) Defined as Titre Above or Equal to 0.6 Bethesda Units (BU)

Interventionalopen25 enrolledStarted 2012-05Completion 2023-1150 sites · Brazil, Canada, Croatia, France…Novo Nordisk A/S